BioWorld

Oct. 29, 2002

Dendreon Gets OK To Resume Enrollment In Phase III Study

Following a six-month delay, Dendreon Corp. received FDA clearance to resume enrollment in its second Phase III trial of Provenge, a therapeutic vaccine for hormone-resistant prostate cancer patients. (BioWorld Today) Read More

Peninsula Raises $22.1M To Fund In-Licensing Program

NIH Scientists Report Finding New Deafness Gene, Mucolipin By Name, Joining Worldwide Panoply Of Same

Abbott's Humira Continues To Impress In RA Treatment

Other News To Note

Correction

Endo's Second Phase III For MorphiDex Misses Endpoint

Aphton Reports Phase III Results Showing G17DT Extends Survival

Today's news in brief

BioWorld

ADPD 2026: Can we prevent dementia? Scientists quantify it

BioWorld

Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...

Illustration of Alzheimer's disease in the brain

ADPD 2026: Three inflection points to target Alzheimer’s disease

BioWorld Science

A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...

News in brief

BioWorld Asia

BioWorld Asia briefs for March 17, 2026

SERCA inhibitor from Sumitomo shows promise for MSA-C treatment

BioWorld Science

At the ongoing International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders (AD/PD 2026) in Copenhagen, Sumitomo Pharma Co....